Cipla invests $21 mn in Chase Pharma for Alzheimer's drug development

Chase Pharma is an early stage drug development company

Indian pharma major Limited, has made a $21-million investment in US-based Chase Pharmaceuticals Corporation Inc., through its wholly owned subsidiary, (EU) Limited, UK. Chase is an early stage drug development company, based in Washington DC.

Chase is focused on developing novel approaches to improve treatments for Alzheimer’s disease. According to the statement, Chase has a unique patented approach and is focused on improving the efficacy, safety and tolerability of existing Alzheimer medications.

The $21 million two-phase financing will support Phase 2a and Phase 2b clinical trials for Chase’s lead drug CPC 201. The original venture funding for Chase was provided by the Brain Trust Accelerator Fund in 2010.

In addition to financing Chase, will collaborate with the company to develop the drug. If successful, may provide low cost access to Chase’s lead drug in India and South Africa. – through its impact investment unit New Ventures – is investing in the Series B round of financing as part of a syndicate, which also consists of Edmond de Rothschild Investment Partners and New Rhein Healthcare LLC.

Subhanu Saxena, MD & Global CEO, Ltd said: “This investment is consistent with New Ventures’ mission to build more innovation-led business streams for in the future. We want to bring affordable medicines, where we identify an unmet patient need, in a way that leverages Cipla’s formidable technology, device and development capabilities.”

In India, over 5 million patients suffer from dementia, most of whom are afflicted with Alzheimer’s. These numbers are expected to double by 2030.  

Shares of are traded at Rs 385, down by 1.92% on BSE.

image
Business Standard
177 22
Business Standard

Cipla invests $21 mn in Chase Pharma for Alzheimer's drug development

Chase Pharma is an early stage drug development company

BS Reporter  |  Mumbai 



Indian pharma major Limited, has made a $21-million investment in US-based Chase Pharmaceuticals Corporation Inc., through its wholly owned subsidiary, (EU) Limited, UK. Chase is an early stage drug development company, based in Washington DC.

Chase is focused on developing novel approaches to improve treatments for Alzheimer’s disease. According to the statement, Chase has a unique patented approach and is focused on improving the efficacy, safety and tolerability of existing Alzheimer medications.



The $21 million two-phase financing will support Phase 2a and Phase 2b clinical trials for Chase’s lead drug CPC 201. The original venture funding for Chase was provided by the Brain Trust Accelerator Fund in 2010.

In addition to financing Chase, will collaborate with the company to develop the drug. If successful, may provide low cost access to Chase’s lead drug in India and South Africa. – through its impact investment unit New Ventures – is investing in the Series B round of financing as part of a syndicate, which also consists of Edmond de Rothschild Investment Partners and New Rhein Healthcare LLC.

Subhanu Saxena, MD & Global CEO, Ltd said: “This investment is consistent with New Ventures’ mission to build more innovation-led business streams for in the future. We want to bring affordable medicines, where we identify an unmet patient need, in a way that leverages Cipla’s formidable technology, device and development capabilities.”

In India, over 5 million patients suffer from dementia, most of whom are afflicted with Alzheimer’s. These numbers are expected to double by 2030.  

Shares of are traded at Rs 385, down by 1.92% on BSE.

RECOMMENDED FOR YOU

Cipla invests $21 mn in Chase Pharma for Alzheimer's drug development

Chase Pharma is an early stage drug development company

Chase Pharma is an early stage drug development company Indian pharma major Limited, has made a $21-million investment in US-based Chase Pharmaceuticals Corporation Inc., through its wholly owned subsidiary, (EU) Limited, UK. Chase is an early stage drug development company, based in Washington DC.

Chase is focused on developing novel approaches to improve treatments for Alzheimer’s disease. According to the statement, Chase has a unique patented approach and is focused on improving the efficacy, safety and tolerability of existing Alzheimer medications.

The $21 million two-phase financing will support Phase 2a and Phase 2b clinical trials for Chase’s lead drug CPC 201. The original venture funding for Chase was provided by the Brain Trust Accelerator Fund in 2010.

In addition to financing Chase, will collaborate with the company to develop the drug. If successful, may provide low cost access to Chase’s lead drug in India and South Africa. – through its impact investment unit New Ventures – is investing in the Series B round of financing as part of a syndicate, which also consists of Edmond de Rothschild Investment Partners and New Rhein Healthcare LLC.

Subhanu Saxena, MD & Global CEO, Ltd said: “This investment is consistent with New Ventures’ mission to build more innovation-led business streams for in the future. We want to bring affordable medicines, where we identify an unmet patient need, in a way that leverages Cipla’s formidable technology, device and development capabilities.”

In India, over 5 million patients suffer from dementia, most of whom are afflicted with Alzheimer’s. These numbers are expected to double by 2030.  

Shares of are traded at Rs 385, down by 1.92% on BSE.
image
Business Standard
177 22
Widgets Magazine

More News

  • Brands learn to play the game Is penalising brand ambassadors a fair move?
  • A technician works inside the ONGC group gathering station on the outskirts of Ahmedabad. Photo: Reuters Shah panel to submit report on ONGC-RIL gas dispute today
Widgets Magazine
Widgets Magazine

Upgrade To Premium Services

Welcome User

Business Standard is happy to inform you of the launch of "Business Standard Premium Services"

As a premium subscriber you get an across device unfettered access to a range of services which include:

  • Access Exclusive content - articles, features & opinion pieces
  • Weekly Industry/Genre specific newsletters - Choose multiple industries/genres
  • Access to 17 plus years of content archives
  • Set Stock price alerts for your portfolio and watch list and get them delivered to your e-mail box
  • End of day news alerts on 5 companies (via email)
  • NEW: Get seamless access to WSJ.com at a great price. No additional sign-up required.
 

Premium Services

In Partnership with

 

Dear Guest,

 

Welcome to the premium services of Business Standard brought to you courtesy FIS.
Kindly visit the Manage my subscription page to discover the benefits of this programme.

Enjoy Reading!
Team Business Standard